Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
IgG4-related disease
Advertisement
FDA Approves Updated 2025–2026 COVID-19 Vaccines from Pfizer, Moderna, and Novavax
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
FDA Ends Broad Emergency Authorization, Approves Updated COVID-19 Vaccines
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
AbbVie Acquires Gilgamesh Pharmaceuticals’ Bretisilocin, A Novel Psychedelic Therapy for Major Depressive Disorder
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...
FDA Approval of PharmaTher’s Ketamine Product KETARx
PharmaTher Holdings Ltd. announced FDA approval of KETARx™, its ketamine product for anesthesia and sedation, marking a significant milestone...
Advertisements
Terumo Acquires OrganOx: A New Era in Organ Preservation
Terumo Corporation is acquiring UK-based OrganOx Limited for approximately USD 1.5 billion, enhancing its entry into the organ transplantation...
EVERSANA and Waltz Health Merger: Redefining Pharma Commercialization
EVERSANA and Waltz Health announced a merger today to form a unified healthcare platform designed to redefine pharmaceutical commercialization...
Harmony Biosciences to Spotlight Rare Epilepsy Pipeline at International Epilepsy Congress
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced today that it will present new clinical data on its investigational therapy...
CorrectSequence Therapeutics Promising Results for World’s First Cure of Sickle Cell via transformer Base Editing
Shanghai, China, August 26, 2025 – In a landmark advancement, CorrectSequence Therapeutics Co., Ltd. (Correctseq) has announced the first...
Sanofi’s Rilzabrutinib Gets EU Orphan Drug Status for IgG4-Related Disease
Paris, August 14, 2025 – The European Medicines Agency (EMA) has granted orphan drug designation to Sanofi’s rilzabrutinib, a...
Advertisement
